Blog

Upcoming Conferences to Attend

NMVB Annual Virtual Meeting (September 23, 2024)

Save the date for the online conference to be held on September 23, 2024. We will have a variety of speakers and presentations all related to how NMVB is doing and where it is headed in the future.

MARF Presents: The International Symposium on Malignant Mesothelioma (October 17 and 18, 2024 in Chicago)

The Meso Foundation’s International Symposium on Malignant Mesothelioma is a unique conference that brings together the entire mesothelioma community. We invite patients, their families, caregivers, and the bereaved community, to learn about the latest in treatment options, speak face-to-face with top mesothelioma experts, and find community and support with others walking in their shoes.

Learn More

Monticello III (October 21 – 25 in Charlottesville, VA)

NMVB’s lead Michael J. Becich will be at the conference to present the topic of “A Path to Asbestos Threshold Determination for Mesothelioma Using Biobanks” on October 23rd between 1:20 PM and 5:40. Contact us for more information.

Karthika Venugopalan

Karthika Venugopalan is a 2nd-year medical student at Lincoln Memorial University – DeBusk College of Osteopathic Medicine (LMU-DCOM) in Tennessee. Before medical school, she spent 2 years at Quest Diagnostics in a Leadership Development Program, which focused on operations-based project management and continuous improvement initiatives. This experience sparked her interest in laboratory medicine and deepened her passion for pathology. She is fascinated by the world of pathology, and its profound impact on patients’ lives – every “patient” (slide) tells a unique story, and each diagnosis can significantly influence a patient’s care plan/treatment trajectory.

This summer, she spent 8 weeks in the Klionsky Pathology Summer Research Fellowship at the University of Pittsburgh, under the mentorship of Dr. Michael Becich and Dr. Ye Ye on the NMVB team. She is incredibly grateful for the knowledge and experiences she has gained during her time with this fantastic team. NMVB plays a crucial role in patient care for those with mesothelioma, and she is glad to have contributed in a small but meaningful way. She learned about pathology informatics, computational pathology, the research process, and mesothelioma – a rare, aggressive form of cancer.

Her primary focus this summer was to establish a framework and explore the integration potential of Prov-GigaPath, a foundational model created by Microsoft, with the National Mesothelioma Virtual Bank (NMVB). By developing this integration framework, the goal is to gain deeper insights into mesothelioma, enhancing research outcomes and improving data sharing capabilities through collaboration with other institutions and researchers. The study aims to create more enhanced and robust workflows for integration. This will enable researchers to handle large datasets effectively and will drive forward innovations in computational pathology.

She is deeply grateful for this opportunity and excited about the future of pathology informatics and digital pathology. She looks forward to applying the knowledge and skills she has gained from her summer experiences as she continues her journey to becoming a pathologist.

R. Taylor Ripley

Dr. R. Taylor Ripley serves as the Director of the Mesothelioma Treatment Center and is a highly esteemed, board-certified thoracic surgeon with a specialization in mesothelioma and thoracic surgical oncology. His expertise extends to chest wall tumors, lung cancer, esophageal cancer and thymoma/thymic carcinoma.

Dr. Ripley is renowned for his proficiency in robotic surgery, which allows him to perform minimally invasive procedures for various thoracic diseases. His skills also encompass a wide range of general thoracic surgery aspects, including infectious lung disease, benign esophageal conditions and endoluminal interventions.

Before joining the faculty at Baylor College of Medicine, Dr. Ripley held the position of Associate Professor of Surgery at the National Cancer Institute, NIH. During his tenure at NIH, he received the NCI Director’s Innovation Award for his groundbreaking work on targeting specific p53-mutations for treating esophageal adenocarcinoma. He established the Foregut Team at the NIH Clinical Center, dedicated to managing patients with esophageal cancer, and initiated robotic thoracic surgery at the NCI, NIH. His research also focused on metabolic reprogramming of thoracic cancer.

Dr. Ripley’s extensive training includes a fellowship at Memorial Sloan-Kettering Cancer Center in New York, where he received expert guidance in caring for patients with mesothelioma from world-renowned surgeons. Additionally, he completed a fellowship in Surgical Oncology at the NCI, NIH, following his general surgery residency at the University of Colorado. He earned his Medical Doctorate from Vanderbilt University.